|         |                                                                                                                                                           |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | Net income from continuing operations attributable to DaVita Inc. for the quarter ended March 31, 2018 was $191 million, or $1.05 per share. |

|         |                                                                                                                                                                                                                                                                                                                              |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | Net income from continuing operations attributable to DaVita Inc. for the quarter ended March 31, 2017 was $441 million, or $2.26 per share. Adjusted net income from continuing operations attributable to DaVita Inc. for the quarter ended March 31, 2017 was $147 million, or $0.75 per share. |

----

|         |                                                                                                                            |
|---------|----------------------------------------------------------------------------------------------------------------------------|
| • | We still expect our Kidney Care consolidated operating income for 2018 to be in the range of $1.5 billion to $1.6 billion. |

|         |                                                                                                                                 |
|---------|---------------------------------------------------------------------------------------------------------------------------------|
| • | We still expect our operating cash flow from continuing operations for 2018 to be in the range of $1.4 billion to $1.6 billion. |

|         |                                                                                                             |
|---------|-------------------------------------------------------------------------------------------------------------|
| • | We still expect our 2018 effective tax rate attributable to DaVita Inc. to be approximately 26.5% to 27.5%. |

----

----

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | the concentration of profits generated by higher-paying commercial payor plans for which there is continued downward pressure on average realized payment rates, and a reduction in the number of patients under such plans, including as a result of restrictions or prohibitions on the use and/or availability of charitable premium assistance, which may result in the loss of revenues or patients, or our making incorrect assumptions about how our patients will respond to any change in financial assistance from charitable organizations; |

|         |                                                                                                                                                                                                                                                                                                                                                                     |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | the extent to which the ongoing implementation of healthcare exchanges or changes in or new legislation, regulations or guidance, or enforcement thereof, including among other things those regarding the exchanges, results in a reduction in reimbursement rates for our services from and/or the number of patients enrolled in higher-paying commercial plans; |

|         |                                                                                                                                |
|---------|--------------------------------------------------------------------------------------------------------------------------------|
| • | a reduction in government payment rates under the Medicare End Stage Renal Disease program or other government-based programs; |

|         |                                                           |
|---------|-----------------------------------------------------------|
| • | the impact of the Medicare Advantage benchmark structure; |

|         |                                                                                                                                                                     |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | risks arising from potential and proposed federal and/or state legislation or regulation, including healthcare-related and labor-related legislation or regulation; |

|         |                                                                                                                                                                                                                                                                                          |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | the impact of the changing political environment and related developments on the current health care marketplace and on our business, including with respect to the future of the Affordable Care Act, the exchanges and many other core aspects of the current health care marketplace; |

|         |                                                                        |
|---------|------------------------------------------------------------------------|
| • | uncertainties related to the impact of federal tax reform legislation; |

|         |                                                                                                                                                                    |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | changes in pharmaceutical practice patterns, reimbursement and payment policies and processes, or pharmaceutical pricing, including with respect to calcimimetics; |

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | legal compliance risks, such as our continued compliance with complex government regulations and the provisions of our current corporate integrity agreement and current or potential investigations by various government entities and related government or private-party proceedings, and restrictions on our business and operations required by our corporate integrity agreement and other current or potential settlement terms, and the financial impact thereof and our ability to recover any losses related to such legal matters from third parties; |

|         |                                                                                                                                           |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------|
| • | continued increased competition from large- and medium-sized dialysis providers and others who compete, or will compete directly with us; |

|         |                                                                                                                                                                                                            |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | our ability to reduce administrative expenses while maintaining targeted levels of service and operating performance, including our ability to achieve anticipated savings from our recent restructurings; |

|         |                                                                                                                                                                                                                                            |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | our ability to maintain contracts with physician medical directors, changing affiliation models for physicians, and the emergence of new models of care introduced by the government or private sector that may erode our patient base and |

----

|         |                                                                                                                                                                                                                                                                                                                                                                      |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | our ability to complete acquisitions, mergers or dispositions that we might announce or be considering, on terms favorable to us or at all, or to integrate and successfully operate any business we may acquire or have acquired, or to successfully expand our operations and services to markets outside the United States, or to businesses outside of dialysis; |

|         |                                                                                                                                                                                                       |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | noncompliance by us or our business associates with any privacy laws or any security breach involving the misappropriation, loss or other unauthorized use or disclosure of confidential information; |

|         |                                    |
|---------|------------------------------------|
| • | the variability of our cash flows; |

|         |                                                                                                                                                                                                                                                                                                                          |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | factors that may impact our ability to repurchase stock under our stock repurchase program and the timing of any such stock repurchases, including market conditions, the price of our common stock, our cash flow position, borrowing capacity and leverage ratios, and legal, regulatory and contractual requirements; |

|         |                                                                                                                                                                                                                                                   |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | the risk that we might invest material amounts of capital and incur significant costs in connection with the growth and development of our international operations, yet we might not be able to operate them profitably anytime soon, if at all; |

|         |                                                                                                                |
|---------|----------------------------------------------------------------------------------------------------------------|
| • | risks arising from the use of accounting estimates, judgments and interpretations in our financial statements; |

|         |                                                          |
|---------|----------------------------------------------------------|
| • | impairment of our goodwill, investments or other assets; |

|         |                                                                                                                                                                                                                                                                                                                                   |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | the risks and uncertainties associated with the timing, conditions and receipt of regulatory approvals and satisfaction of other closing conditions of the DMG sale transaction and potential disruption in connection with the DMG sale transaction making it more difficult to maintain business and operational relationships; |

|         |                                                                                                                                |
|---------|--------------------------------------------------------------------------------------------------------------------------------|
| • | the risk that laws regulating the corporate practice of medicine could restrict the manner in which DMG conducts its business; |

|         |                                                                                                        |
|---------|--------------------------------------------------------------------------------------------------------|
| • | the risk that the cost of providing services under DMG’s agreements may exceed our compensation; |

|         |                                                                                                                                                                                    |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | the risk that reductions in reimbursement rates, including Medicare Advantage rates, and future regulations may negatively impact DMG’s business, revenue and profitability; |

|         |                                                                                                                                                                                   |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | the risk that DMG may not be able to successfully establish a presence in new geographic regions or successfully address competitive threats that could reduce its profitability; |

|         |                                                                                                                                                           |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | the risk that a disruption in DMG’s healthcare provider networks could have an adverse effect on DMG’s business operations and profitability; |

|         |                                                                                                                                                                    |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | the risk that reductions in the quality ratings of health maintenance organization plan customers of DMG could have an adverse effect on DMG’s business; and |

|         |                                                                                                                                                                              |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | the risk that health plans that acquire health maintenance organizations may not be willing to contract with DMG or may be willing to contract only on less favorable terms. |

----

|                                                                                     |
|-------------------------------------------------------------------------------------|
|                                                                                     |  |  |  |  |  |  |  |
|                                                                                | Three months ended March 31, |
|                                                                                | 2018 |   | 2017 |
| Dialysis and related lab patient service revenues                                   | $ | 2,591,074 |  |   | $ | 2,422,786 |  |
| Provision for uncollectible accounts                                                | 25,545 |  |   | (107,058 | ) |
| Net dialysis and related lab patient service revenues                               | 2,616,619 |  |   | 2,315,728 |  |
| Other revenues                                                                      | 232,825 |  |   | 315,523 |  |
| Total revenues                                                                      | 2,849,444 |  |   | 2,631,251 |  |
| Operating expenses and charges:                                                     |   |  |   |   |  |
| Patient care costs and other costs                                                  | 2,035,585 |  |   | 1,852,045 |  |
| General and administrative                                                          | 266,529 |  |   | 262,895 |  |
| Depreciation and amortization                                                       | 142,799 |  |   | 132,884 |  |
| Equity investment income                                                            | (155 | ) |   | (677 | ) |
| Provision for uncollectible accounts                                                | (6,000 | ) |   | 1,910 |  |
| Investment and other asset impairments                                              | — |  |   | 15,168 |  |
| Goodwill impairment charges                                                         | — |  |   | 24,198 |  |
| Gain on changes in ownership interests                                              | — |  |   | (6,273 | ) |
| Gain on settlement, net                                                             | — |  |   | (526,827 | ) |
| Total operating expenses and charges                                                | 2,438,758 |  |   | 1,755,323 |  |
| Operating income                                                                    | 410,686 |  |   | 875,928 |  |
| Debt expense                                                                        | (113,516 | ) |   | (104,397 | ) |
| Other income, net                                                                   | 4,582 |  |   | 3,986 |  |
| Income from continuing operations before income taxes                               | 301,752 |  |   | 775,517 |  |
| Income tax expense                                                                  | 70,737 |  |   | 281,665 |  |
| Net income from continuing operations                                               | 231,015 |  |   | 493,852 |  |
| Net (loss) income from discontinued operations, net of tax                          | (5,786 | ) |   | 6,433 |  |
| Net income                                                                          | 225,229 |  |   | 500,285 |  |
| Less: Net income attributable to noncontrolling interests                           | (46,543 | ) |   | (52,588 | ) |
| Net income attributable to DaVita Inc.                                              | $ | 178,686 |  |   | $ | 447,697 |  |
| Earnings per share:                                                                 |   |  |   |   |  |
| Basic net income from continuing operations per share attributable to DaVita Inc.   | $ | 1.07 |  |   | $ | 2.29 |  |
| Basic net income per share attributable to DaVita Inc.                              | $ | 1.00 |  |   | $ | 2.33 |  |
| Diluted net income from continuing operations per share attributable to DaVita Inc. | $ | 1.05 |  |   | $ | 2.26 |  |
| Diluted net income per share attributable to DaVita Inc.                            | $ | 0.98 |  |   | $ | 2.29 |  |
| Weighted average shares for earnings per share:                                     |   |   |   |
| Basic                                                                               | 178,957,865 |  |   | 192,376,735 |  |
| Diluted                                                                             | 181,834,547 |  |   | 195,281,014 |  |
| Amounts attributable to DaVita Inc.:                                                |   |   |   |
| Net income from continuing operations                                               | $ | 191,015 |  |   | $ | 440,905 |  |
| Net (loss) income from discontinued operations                                      | (12,329 | ) |   | 6,792 |  |
| Net income attributable to DaVita Inc.                                              | $ | 178,686 |  |   | $ | 447,697 |  |

----

|                                                                                          |
|------------------------------------------------------------------------------------------|
|                                                                                          |  |  |  |  |  |  |  |
|                                                                                     | Three months endedMarch 31, |
|                                                                                     | 2018 |   | 2017 |
| Net income                                                                               | $ | 225,229 |  |   | $ | 500,285 |  |
| Other comprehensive income, net of tax:                                                  |   |  |   |   |  |
| Unrealized gains (losses) on interest rate cap agreements:                               |   |  |   |   |  |
| Unrealized gains (losses) on interest rate cap agreements                                | 1,050 |  |   | (3,188 | ) |
| Reclassifications of net realized losses on interest rate cap agreements into net income | 1,537 |  |   | 1,265 |  |
| Unrealized gains on investments:                                                         |   |   |   |
| Unrealized gains on investments                                                          | — |  |   | 1,557 |  |
| Reclassification of net investment realized gains into net income                        | — |  |   | (140 | ) |
| Unrealized gains on foreign currency translation:                                        |   |   |   |  |
| Foreign currency translation adjustments                                                 | 19,881 |  |   | 13,261 |  |
| Other comprehensive income                                                               | 22,468 |  |   | 12,755 |  |
| Total comprehensive income                                                               | 247,697 |  |   | 513,040 |  |
| Less: Comprehensive income attributable to noncontrolling interests                      | (46,543 | ) |   | (52,586 | ) |
| Comprehensive income attributable to DaVita Inc.                                         | $ | 201,154 |  |   | $ | 460,454 |  |

----

|                                                                                              |
|----------------------------------------------------------------------------------------------|
|                                                                                              |  |  |  |  |  |  |  |
|                                                                                         | Three months endedMarch 31, |
|                                                                                         | 2018 |   | 2017 |
| Cash flows from operating activities:                                                        |   |  |   |   |  |
| Net income                                                                                   | $ | 225,229 |  |   | $ | 500,285 |  |
| Adjustments to reconcile net income to net cash provided by operating activities:            |   |   |   |  |
| Depreciation and amortization                                                                | 142,799 |  |   | 190,206 |  |
| Impairment charges                                                                           | — |  |   | 39,366 |  |
| Stock-based compensation expense                                                             | 9,685 |  |   | 9,601 |  |
| Deferred income taxes                                                                        | 43,617 |  |   | 20,091 |  |
| Equity investment income, net                                                                | 3,564 |  |   | 1,423 |  |
| Other non-cash charges, net                                                                  | 9,959 |  |   | 9,464 |  |
| Changes in operating assets and liabilities, net of effect of acquisitions and divestitures: |   |   |   |
| Accounts receivable                                                                          | (63,701 | ) |   | 16,168 |  |
| Inventories                                                                                  | 57,621 |  |   | (8,909 | ) |
| Other receivables and other current assets                                                   | (34,120 | ) |   | (84,511 | ) |
| Other long-term assets                                                                       | 2,054 |  |   | (2,310 | ) |
| Accounts payable                                                                             | (62,830 | ) |   | (26,214 | ) |
| Accrued compensation and benefits                                                            | (62,550 | ) |   | (62,825 | ) |
| Other current liabilities                                                                    | 49,379 |  |   | (9,633 | ) |
| Income taxes                                                                                 | 30,772 |  |   | 258,490 |  |
| Other long-term liabilities                                                                  | 11,061 |  |   | 14,479 |  |
| Net cash provided by operating activities                                                    | 362,539 |  |   | 865,171 |  |
| Cash flows from investing activities:                                                        |   |   |   |  |
| Additions of property and equipment                                                          | (232,443 | ) |   | (214,535 | ) |
| Acquisitions                                                                                 | (16,582 | ) |   | (77,236 | ) |
| Proceeds from asset and business sales                                                       | 18,535 |  |   | 46,612 |  |
| Purchase of investments available for sale                                                   | (2,646 | ) |   | (2,358 | ) |
| Purchase of investments held-to-maturity                                                     | (3,586 | ) |   | (121,645 | ) |
| Proceeds from sale of investments available for sale                                         | 5,151 |  |   | 4,025 |  |
| Proceeds from investments held-to-maturity                                                   | 31,454 |  |   | 116,285 |  |
| Purchase of equity investments                                                               | (2,476 | ) |   | (1,135 | ) |
| Distributions received on equity investments                                                 | 2,465 |  |   | — |  |
| Net cash used in investing activities                                                        | (200,128 | ) |   | (249,987 | ) |

----

|                                                                                                  |
|--------------------------------------------------------------------------------------------------|
|                                                                                                  |  |  |  |  |  |  |  |
|                                                                                             | Three months endedMarch 31, |
|                                                                                             | 2018 |   | 2017 |
| Cash flows from financing activities:                                                            |   |   |   |
| Borrowings                                                                                       | 13,306,898 |  |   | 12,803,015 |  |
| Payments on long-term debt and other financing costs                                             | (13,202,225 | ) |   | (12,839,156 | ) |
| Purchase of treasury stock                                                                       | (290,377 | ) |   | — |  |
| Stock award exercises and other share issuances, net                                             | (1,185 | ) |   | 3,330 |  |
| Distributions to noncontrolling interests                                                        | (45,467 | ) |   | (43,316 | ) |
| Contributions from noncontrolling interests                                                      | 12,009 |  |   | 17,989 |  |
| Purchases of noncontrolling interests                                                            | (2,200 | ) |   | (799 | ) |
| Net cash used in financing activities                                                            | (222,547 | ) |   | (58,937 | ) |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash                    | 6,668 |  |   | 2,820 |  |
| Net (decrease) increase in cash, cash equivalents and restricted cash                            | (53,468 | ) |   | 559,067 |  |
| Less: Net increase in cash, cash equivalents and restricted cash from discontinued operations    | 17,834 |  |   | 24,493 |  |
| Net (decrease) increase in cash, cash equivalents and restricted cash from continuing operations | (71,302 | ) |   | 534,574 |  |
| Cash, cash equivalents and restricted cash of continuing operations at beginning of the year     | 518,920 |  |   | 683,463 |  |
| Cash, cash equivalents and restricted cash of continuing operations at end of the period         | $ | 447,618 |  |   | $ | 1,218,037 |  |

----

|                                                                                                                                                                            |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                            |  |  |  |  |  |  |  |
|                                                                                                                                                                       | March 31, 2018 |   | December 31, 2017 |
| ASSETS                                                                                                                                                                     |   |  |   |   |  |
| Cash and cash equivalents                                                                                                                                                  | $ | 358,874 |  |   | $ | 508,234 |  |
| Restricted cash and equivalents                                                                                                                                            | 88,744 |  |   | 10,686 |  |
| Short-term investments                                                                                                                                                     | 4,602 |  |   | 32,830 |  |
| Accounts receivable, net                                                                                                                                                   | 1,830,590 |  |   | 1,714,750 |  |
| Inventories                                                                                                                                                                | 125,555 |  |   | 181,799 |  |
| Other receivables                                                                                                                                                          | 415,914 |  |   | 372,919 |  |
| Income tax receivable                                                                                                                                                      | 18,660 |  |   | 49,440 |  |
| Prepaid and other current assets                                                                                                                                           | 106,351 |  |   | 112,058 |  |
| Current assets held for sale                                                                                                                                               | 5,724,265 |  |   | 5,761,642 |  |
| Total current assets                                                                                                                                                       | 8,673,555 |  |   | 8,744,358 |  |
| Property and equipment, net of accumulated depreciation of $3,230,717 and $3,103,662                                                                                       | 3,185,223 |  |   | 3,149,213 |  |
| Intangible assets, net of accumulated amortization of $360,828 and $356,774                                                                                                | 113,366 |  |   | 113,827 |  |
| Equity method and other investments                                                                                                                                        | 245,564 |  |   | 245,534 |  |
| Long-term investments                                                                                                                                                      | 34,344 |  |   | 37,695 |  |
| Other long-term assets                                                                                                                                                     | 51,728 |  |   | 47,287 |  |
| Goodwill                                                                                                                                                                   | 6,638,592 |  |   | 6,610,279 |  |
|                                                                                                                                                                       | $ | 18,942,372 |  |   | $ | 18,948,193 |  |
| LIABILITIES AND EQUITY                                                                                                                                                     |   |  |   |   |  |
| Accounts payable                                                                                                                                                           | $ | 437,733 |  |   | $ | 509,116 |  |
| Other liabilities                                                                                                                                                          | 544,846 |  |   | 552,662 |  |
| Accrued compensation and benefits                                                                                                                                          | 526,183 |  |   | 616,116 |  |
| Current portion of long-term debt                                                                                                                                          | 184,136 |  |   | 178,213 |  |
| Current liabilities held for sale                                                                                                                                          | 1,254,625 |  |   | 1,185,070 |  |
| Total current liabilities                                                                                                                                                  | 2,947,523 |  |   | 3,041,177 |  |
| Long-term debt                                                                                                                                                             | 9,279,885 |  |   | 9,158,018 |  |
| Other long-term liabilities                                                                                                                                                | 391,156 |  |   | 365,325 |  |
| Deferred income taxes                                                                                                                                                      | 507,226 |  |   | 486,247 |  |
| Total liabilities                                                                                                                                                          | 13,125,790 |  |   | 13,050,767 |  |
| Commitments and contingencies:                                                                                                                                             |   |   |   |
| Noncontrolling interests subject to put provisions                                                                                                                         | 1,034,501 |  |   | 1,011,360 |  |
| Equity:                                                                                                                                                                    |   |  |   |   |  |
| Preferred stock ($0.001 par value, 5,000,000 shares authorized; none issued)                                                                                               |   |  |   |   |  |
| Common stock ($0.001 par value, 450,000,000 shares authorized; 182,660,712 and 182,462,278 shares issued and 178,463,408 and 182,462,278 shares outstanding, respectively) | 183 |  |   | 182 |  |
| Additional paid-in capital                                                                                                                                                 | 1,030,772 |  |   | 1,042,899 |  |
| Retained earnings                                                                                                                                                          | 3,820,767 |  |   | 3,633,713 |  |
| Treasury stock (4,197,304 and zero shares, respectively)                                                                                                                   | (298,377 | ) |   | — |  |
| Accumulated other comprehensive income                                                                                                                                     | 27,335 |  |   | 13,235 |  |
| Total DaVita Inc. shareholders' equity                                                                                                                                     | 4,580,680 |  |   | 4,690,029 |  |
| Noncontrolling interests not subject to put provisions                                                                                                                     | 201,401 |  |   | 196,037 |  |
| Total equity                                                                                                                                                               | 4,782,081 |  |   | 4,886,066 |  |
|                                                                                                                                                                       | $ | 18,942,372 |  |   | $ | 18,948,193 |  |

----

|                                                                                                                          |
|--------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                          |  |  |  |  |  |  |  |  |  |  |  |
|                                                                                                                     | Three months ended |
|                                                                                                                     | March 31,2018 |   | December 31,2017 |   | March 31,2017 (1) |
| 1. Consolidated Financial Results:                                                                                       |   |   |   |   |   |
| Consolidated revenues(2)                                                                                                 | $ | 2,849 |  |   | $ | 2,781 |  |   | $ | 2,631 |  |
| Operating income                                                                                                         | $ | 411 |  |   | $ | 150 |  |   | $ | 876 |  |
| Adjusted operating income excluding certain items(3)                                                                     | $ | 411 |  |   | $ | 430 |  |   | $ | 380 |  |
| Operating income margin                                                                                                  | 14.4 | % |   | 5.4 |  % |   | 33.3 | % |
| Adjusted operating income margin excluding certain items(3) (7)                                                          | 14.4 | % |   | 15.5 |  % |   | 14.4 | % |
| Net income from continuing operations attributable to DaVita Inc.                                                        | $ | 191 |  |   | $ | 156 |  |   | $ | 441 |  |
| Adjusted net income from continuing operations attributable to DaVita Inc. excluding certain items(3)                    | $ | 191 |  |   | $ | 170 |  |   | $ | 147 |  |
| Diluted net income from continuing operations per share attributable to DaVita Inc.                                      | $ | 1.05 |  |   | $ | 0.85 |  |   | $ | 2.26 |  |
| Adjusted diluted net income from continuing operations per share attributable to DaVita Inc. excluding certain items (3) | $ | 1.05 |  |   | $ | 0.92 |  |   | $ | 0.75 |  |
|                                                                                                                     |   |   |   |   |   |
| 2. Consolidated Business Metrics:                                                                                        |   |   |   |   |   |
| Expenses                                                                                                                 |   |   |   |   |   |
| General and administrative expenses as a percent of consolidated revenues(4)                                        | 9.4 | % |   | 9.5 |  % |   | 10.0 | % |
| Effective tax rate                                                                                                       | 23.4 | % |   | (320.9 | )% |   | 36.3 | % |
| Effective tax rate attributable to DaVita Inc.(3)                                                                   | 27.0 | % |   | (2,590.5 | )% |   | 39.0 | % |
| Adjusted effective tax rate attributable to DaVita Inc.(3)                                                               | 27.0 | % |   | 40.4 |  % |   | 39.6 | % |
|                                                                                                                     |   |   |   |   |   |
| 3. Summary of Division Financial Results:                                                                                |   |   |   |   |   |
| Revenues(2)                                                                                                              |   |   |   |   |   |
| Kidney Care:                                                                                                             |   |   |   |   |   |
| U.S. dialysis and related lab patient services and other                                                                 | $ | 2,538 |  |   | $ | 2,393 |  |   | $ | 2,271 |  |
| Other—Ancillary services and strategic initiatives                                                                 |   |   |   |   |   |
| U.S. other                                                                                                               | 237 |  |   | 316 |  |   | 315 |  |
| International dialysis patient service and other                                                                         | 103 |  |   | 95 |  |   | 63 |  |
|                                                                                                                     | 340 |  |   | 410 |  |   | 378 |  |
| Eliminations                                                                                                             | (29 | ) |   | (23 | ) |   | (18 | ) |
| Total consolidated revenues                                                                                              | $ | 2,849 |  |   | $ | 2,781 |  |   | $ | 2,631 |  |
| Operating income (loss)                                                                                                  |   |   |   |   |   |
| Kidney Care:                                                                                                             |   |   |   |   |   |
| U.S. dialysis and related lab services                                                                                   | $ | 433 |  |   | $ | 459 |  |   | $ | 945 |  |
| Other—Ancillary services and strategic initiatives                                                                 |   |   |   |   |   |
| U.S.                                                                                                                     | (5 | ) |   | (2 | ) |   | (53 | ) |
| International                                                                                                            | (2 | ) |   | (294 | ) |   | (5 | ) |
|                                                                                                                     | (7 | ) |   | (296 | ) |   | (58 | ) |
| Corporate administrative support                                                                                         | (16 | ) |   | (12 | ) |   | (11 | ) |
| Total consolidated operating income                                                                                      | $ | 411 |  |   | $ | 150 |  |   | $ | 876 |  |

----

|                                                             |
|-------------------------------------------------------------|
|                                                             |  |  |  |  |  |  |  |  |  |  |  |
|                                                        | Three months ended |
|                                                        | March 31,2018 |   | December 31,2017 |   | March 31,2017 (1) |
| 4. Summary of Reportable Segment Financial Results:         |   |   |   |   |   |
| U.S. Dialysis and Related Lab Services                      |   |   |   |   |   |
| Revenue:(2)                                                 |   |   |   |   |   |
| Net dialysis and related lab patient service revenues       | $ | 2,533 |  |   | $ | 2,388 |  |   | $ | 2,266 |  |
| Other revenues                                              | 5 |  |   | 5 |  |   | 5 |  |
| Total operating revenues                                    | 2,538 |  |   | 2,393 |  |   | 2,271 |  |
| Operating expenses:                                         |   |   |   |   |   |
| Patient care costs                                          | 1,779 |  |   | 1,619 |  |   | 1,548 |  |
| General and administrative                                  | 196 |  |   | 186 |  |   | 188 |  |
| Depreciation and amortization                               | 135 |  |   | 134 |  |   | 125 |  |
| Equity investment income                                    | (5 | ) |   | (5 | ) |   | (8 | ) |
| Gain on settlement, net                                     | — |  |   | — |  |   | (527 | ) |
| Total operating expenses                                    | 2,105 |  |   | 1,934 |  |   | 1,326 |  |
| Segment operating income                                    | $ | 433 |  |   | $ | 459 |  |   | $ | 945 |  |
| Reconciliation for non-GAAP measure:                        |   |   |   |   |   |
| Less:                                                       |   |   |   |   |   |
| Gain on settlement, net                                     | — |  |   | — |  |   | (527 | ) |
| Equity investment income related to gain on settlement      | — |  |   | — |  |   | (3 | ) |
| Adjusted segment operating income(3)                        | $ | 433 |  |   | $ | 459 |  |   | $ | 415 |  |
|                                                        |   |   |   |   |   |
| 5. U.S. Dialysis and Related Lab Services Business Metrics: |   |   |   |   |   |
| Volume                                                      |   |   |   |   |   |
| Treatments                                                  | 7,174,026 |  |   | 7,244,555 |  |   | 6,804,384 |  |
| Number of treatment days                                    | 77.5 |  |   | 78.5 |  |   | 77.0 |  |
| Treatments per day                                          | 92,568 |  |   | 92,287 |  |   | 88,369 |  |
| Per day year over year increase                             | 4.8 | % |   | 5.8 |  % |   | 3.7 |  % |
| Normalized non-acquired treatment growth year over year     | 3.4 | % |   | 3.5 |  % |   | 3.8 |  % |
| Operating net revenues(2)                                   |   |   |   |   |   |
| Dialysis and related lab services net revenue per treatment | $ | 353.05 |  |   | $ | 329.68 |  |   | $ | 333.00 |  |
| Revenue per treatment changes from previous quarter         | 7.1 | % |   | 0.1 |  % |   | (1.0 | )% |
| Revenue per treatment changes from previous year            | 6.0 | % |   | (2.0 | )% |   | (0.5 | )% |
| Percent of consolidated revenues                            | 88.4 | % |   | 85.5 |  % |   | 85.9 |  % |

----

|                                                                         |
|-------------------------------------------------------------------------|
|                                                                         |  |  |  |  |  |  |  |  |  |  |  |
|                                                                    | Three months ended |
|                                                                    | March 31,2018 |   | December 31,2017 |   | March 31,2017 (1) |
| 5. U.S. Dialysis and Related Lab Services Business Metrics: (continued) |   |   |   |   |   |
| Expenses                                                                |   |   |   |   |   |
| Patient care costs                                                      |   |   |   |   |   |
| Percent of total segment operating net revenues                         | 70.1 |  % |   | 67.6 |  % |   | 68.1 |  % |
| Per treatment                                                           | $ | 248.02 |  |   | $ | 223.47 |  |   | $ | 227.47 |  |
| Per treatment changes from previous quarter                             | 11.0 |  % |   | — |  % |   | (0.1 | )% |
| Per treatment changes from previous year                                | 9.0 |  % |   | (1.8 | )% |   | 1.0 |  % |
| General and administrative expenses                                     |   |   |   |   |   |
| Percent of total segment operating net revenues                         | 7.7 |  % |   | 7.8 |  % |   | 8.3 |  % |
| Per treatment                                                           | $ | 27.28 |  |   | $ | 25.67 |  |   | $ | 27.65 |  |
| Per treatment changes from previous quarter                             | 6.3 |  % |   | (6.2 | )% |   | (4.1 | )% |
| Per treatment changes from previous year                                | (1.3 | )% |   | (10.9 | )% |   | 2.5 |  % |
| Accounts receivable                                                     |   |   |   |   |   |
| Net receivables                                                         | 1,620 |  |   | 1,524 |  |   | 1,335 |  |
| DSO                                                                     | 59 |  |   | 60 |  |   | 54 |  |
|                                                                    |   |   |   |   |   |
| 6. Discontinued Operations                                              |   |   |   |   |   |
| Operating results                                                       |   |   |   |   |   |
| Net revenues(2)                                                         | $ | 1,228 |  |   | $ | 1,215 |  |   | $ | 1,087 |  |
| Expenses                                                                | 1,226 |  |   | 1,238 |  |   | 1,075 |  |
| Income (loss) from discontinued operations before taxes                 | 2 |  |   | (23 | ) |   | 12 |  |
| Income tax (expense) benefit                                            | (7 | ) |   | 167 |  |   | (6 | ) |
| Net (loss) income from discontinued operations, net of tax              | $ | (6 | ) |   | $ | 144 |  |   | $ | 6 |  |
|                                                                    |   |   |   |   |   |
| 7. Cash Flow:                                                           |   |   |   |   |   |
| Operating cash flow                                                     | $ | 362.5 |  |   | $ | 342.9 |  |   | $ | 865.2 |  |
| Operating cash flow from continuing operations                          | $ | 206.3 |  |   | $ | 286.7 |  |   | $ | 769.6 |  |
| Operating cash flow from continuing operations, last twelve months      | $ | 992.6 |  |   | $ | 1,555.9 |  |   | $ | 2,105.3 |  |
| Free cash flow from continuing operations(3)                            | $ | 61.6 |  |   | $ | 149.9 |  |   | $ | 657.0 |  |
| Free cash flow from continuing operations, last twelve months(3)        | $ | 446.9 |  |   | $ | 1,042.3 |  |   | $ | 1,610.9 |  |
| Capital expenditures from continuing operations:                        |   |   |   |   |   |
| Routine maintenance/IT/other                                            | $ | 99.3 |  |   | $ | 91.4 |  |   | $ | 69.3 |  |
| Development and relocations                                             | $ | 102.1 |  |   | $ | 151.8 |  |   | $ | 117.4 |  |
| Acquisition expenditures                                                | $ | 15.7 |  |   | $ | 57.0 |  |   | $ | 58.4 |  |
| Proceeds from sale of self-developed properties                         | $ | 18.2 |  |   | $ | 7.0 |  |   | 40.9 |  |

----

|                                                                                                                            |
|----------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                            |  |  |  |  |  |  |  |  |  |  |  |
|                                                                                                                       | Three months ended |
|                                                                                                                       | March 31,2018 |   | December 31,2017 |   | March 31,2017 (1) |
| 8. Debt and Capital Structure:                                                                                             |   |   |   |   |   |
| Total debt(5)(6)                                                                                                           | $ | 9,526 |  |   | $ | 9,400 |  |   | $ | 9,162 |  |
| Net debt, net of cash and cash equivalents(5)(6)                                                                           | $ | 9,167 |  |   | $ | 8,892 |  |   | $ | 7,952 |  |
| Leverage ratio (see calculation on page 15)                                                                                | 3.75x |  |   | 3.63x |  |   | 3.03x |  |
| Overall weighted average effective interest rate during the quarter                                                        | 4.87 | % |   | 4.80 | % |   | 4.55 | % |
| Overall weighted average effective interest rate at end of the quarter                                                     | 4.98 | % |   | 4.88 | % |   | 4.64 | % |
| Weighted average effective interest rate on the senior secured credit facilities at end of the quarter                     | 4.67 | % |   | 4.45 | % |   | 3.95 | % |
| Fixed and economically fixed interest rates as a percentage of our total debt                                              | 51 | % |   | 52 | % |   | 53 | % |
| Fixed and economically fixed interest rates, including our interest rate cap agreements, as a percentage of our total debt | 88 | % |   | 89 | % |   | 91 | % |

|     |                                                                                                                                                                                                                            |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (1) | As a result of the pending sale of DMG announced in December 2017, the DMG business has been classified as held for sale and its results of operations are presented as discontinued operations for all periods presented. |

|     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (2) | On January 1, 2018, the Company adopted FASB Accounting Standards Codification Topic 606 Revenue from Contracts with Customers using the cumulative effect method for those contracts which were not completed as of January 1, 2018. Results for reporting periods beginning on and after January 1, 2018 are presented under Topic 606, while prior period amounts continue to be reported in accordance with our historical accounting under Revenue Recognition (Topic 605). |

|     |                                                                                                                                                                                                                                                                      |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (3) | These are non-GAAP financial measures. For a reconciliation of these non-GAAP financial measures to their most comparable measure calculated and presented in accordance with GAAP, and for a definition of adjusted amounts, see attached reconciliation schedules. |

|     |                                                                                                                                                                                                                                                                           |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (4) | Consolidated percentages of revenues are comprised of the dialysis and related lab services business and other ancillary services and strategic initiatives. General and administrative expenses includes certain corporate support and long-term incentive compensation. |

|     |                                                                                                                                                                                                                                                                                                                                                                                                    |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (5) | The reported balance sheet amounts at March 31, 2018, December 31, 2017, and March 31, 2017, exclude $62.0 million, $64.0 million and $75.9 million, respectively, of a debt discount associated with our Term Loan B and other deferred financing costs. The reported balance sheet amounts exclude DMG debt which is classified as held for sale liabilities for all periods presented. |

|     |                                                                                                                                                                                                |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (6) | The reported total debt and net debt, net of cash and cash equivalents excludes DMG cash and debt classified as held for sale assets and liabilities, respectively, for all periods presented. |

|     |                                                                                                                  |
|-----|------------------------------------------------------------------------------------------------------------------|
| (7) | Adjusted operating income margin is a calculation of adjusted operating income divided by consolidated revenues. |

----

|                                                                                                                        |
|------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                        |  |  |  |
|                                                                                                                   | Rolling twelve months endedMarch 31, 2018 |
| Net income attributable to DaVita Inc.                                                                                 | $ | 394,607 |  |
| Income taxes                                                                                                           | (250,715 | ) |
| Interest expense                                                                                                       | 407,239 |  |
| Depreciation and amortization                                                                                          | 730,077 |  |
| Impairment charges                                                                                                     | 942,223 |  |
| Noncontrolling interests and equity investment income, net                                                             | 193,007 |  |
| Stock-settled stock-based compensation                                                                                 | 35,097 |  |
| Gain on changes in ownership interest, net                                                                             | (17,129 | ) |
| Other                                                                                                                  | 1,552 |  |
| “Consolidated EBITDA”                                                                                      | $ | 2,435,958 |  |
|                                                                                                                   |   |
|                                                                                                                   | March 31, 2018 |
| Total debt, excluding debt discount and other deferred financing costs of $62.0 million                                | $ | 9,563,255 |  |
| Letters of credit issued                                                                                               | 36,917 |  |
|                                                                                                                   | 9,600,172 |  |
| Less: Cash and cash equivalents including short-term investments (excluding DMG’s physician owned entities cash) | (470,088 | ) |
| Consolidated net debt                                                                                                  | $ | 9,130,084 |  |
| Last twelve months “Consolidated EBITDA”                                                                   | $ | 2,435,958 |  |
| Leverage ratio                                                                                                         | 3.75x |  |

----

|         |                                                                                                                                                 |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------|
| Note 2: | Adjusted net income from continuing operations and adjusted diluted net income from continuing operations per share attributable to DaVita Inc. |

|                                                                                              |
|----------------------------------------------------------------------------------------------|
|                                                                                              |  |  |  |  |  |  |  |  |  |  |  |
|                                                                                         | Three months ended |
|                                                                                         | March 31,2018 |   | December 31,2017 |   | March 31,2017 |
| Net income from continuing operations attributable to DaVita Inc.                            | $ | 191,015 |  |   | $ | 156,210 |  |   | $ | 440,905 |  |
| Tax reform                                                                                   | — |  |   | (251,510 | ) |   | — |  |
| Goodwill impairment charges                                                                  | — |  |   | — |  |   | 24,198 |  |
| Impairment of investments                                                                    | — |  |   | 280,066 |  |   | — |  |
| Impairment of other assets                                                                   | — |  |   | — |  |   | 15,168 |  |
| Gain on settlement, net                                                                      | — |  |   | — |  |   | (526,827 | ) |
| Equity investment income related to gain on settlement                                       | — |  |   | — |  |   | (2,677 | ) |
| Gain on APAC JV ownership changes                                                            | — |  |   | — |  |   | (6,273 | ) |
| Noncontrolling interests associated with adjustments:                                        |   |   |   |   |   |
| Goodwill impairment charges                                                                  | — |  |   | — |  |   | (6,880 | ) |
| Gain on settlement, net                                                                      | — |  |   | — |  |   | 24,029 |  |
| Related income tax                                                                           | — |  |   | (14,418 | ) |   | 185,162 |  |
| Adjusted net income from continuing operations attributable to DaVita Inc.                   | $ | 191,015 |  |   | $ | 170,348 |  |   | $ | 146,805 |  |
| Diluted net income from continuing operations per share attributable to DaVita Inc.          | $ | 1.05 |  |   | $ | 0.85 |  |   | $ | 2.26 |  |
| Tax reform                                                                                   | — |  |   | (1.36 | ) |   | — |  |
| Goodwill impairment charges                                                                  | — |  |   | — |  |   | 0.12 |  |
| Impairment of investments                                                                    | — |  |   | 1.52 |  |   | — |  |
| Impairment of other assets                                                                   | — |  |   | — |  |   | 0.08 |  |
| Gain on settlement, net                                                                      | — |  |   | — |  |   | (2.70 | ) |
| Equity investment income related to gain on settlement                                       | — |  |   | — |  |   | (0.01 | ) |
| Gain on APAC JV ownership changes                                                            | — |  |   | — |  |   | (0.03 | ) |
| Noncontrolling interests associated with adjustments:                                        |   |   |   |   |   |
| Goodwill impairment charges                                                                  | — |  |   | — |  |   | (0.04 | ) |
| Gain on settlement, net                                                                      | — |  |   | — |  |   | 0.12 |  |
| Related income tax                                                                           | — |  |   | (0.08 | ) |   | 0.95 |  |
| Adjusted diluted net income from continuing operations per share attributable to DaVita Inc. | $ | 1.05 |  |   | $ | 0.92 |  |   | $ | 0.75 |  |

----

|                                                        |
|--------------------------------------------------------|
|                                                        |  |  |  |  |  |  |  |  |  |  |  |
|                                                   | Three months ended |
|                                                   | March 31,2018 |   | December 31,2017 |   | March 31,2017 |
| Consolidated:                                          |   |   |   |   |   |
| Operating income                                       | $ | 410,686 |  |   | $ | 150,337 |  |   | $ | 875,928 |  |
| Goodwill impairment charges                            | — |  |   | — |  |   | 24,198 |  |
| Impairment of investments                              | — |  |   | 280,066 |  |   | — |  |
| Impairment of other assets                             | — |  |   | — |  |   | 15,168 |  |
| Gain on settlement, net                                | — |  |   | — |  |   | (526,827 | ) |
| Equity investment income related to gain on settlement | — |  |   | — |  |   | (2,677 | ) |
| Gain on APAC JV ownership changes                      | — |  |   | — |  |   | (6,273 | ) |
| Adjusted operating income                              | $ | 410,686 |  |   | $ | 430,403 |  |   | $ | 379,517 |  |

|                                                                                   |
|-----------------------------------------------------------------------------------|
|                                                                                   |  |  |  |  |  |  |  |  |  |  |  |
|                                                                              | Three months ended |
|                                                                              | March 31,2018 |   | December 31,2017 |   | March 31,2017 |
| Kidney Care:                                                                      |   |   |   |   |   |
| U.S. dialysis and related lab services:                                           |   |   |   |   |   |
| Segment operating income                                                          | $ | 433,380 |  |   | $ | 459,210 |  |   | $ | 944,740 |  |
| Gain on settlement, net                                                           | — |  |   | — |  |   | (526,827 | ) |
| Equity investment income related to gain on settlement                            | — |  |   | — |  |   | (2,677 | ) |
| Adjusted U.S. dialysis and related lab services operating income                  | 433,380 |  |   | 459,210 |  |   | 415,236 |  |
| Other - Ancillary services and strategic initiatives:                             |   |   |   |   |   |
| U.S.                                                                              |   |   |   |   |   |
| Segment operating loss                                                            | (5,186 | ) |   | (2,452 | ) |   | (53,027 | ) |
| Goodwill impairment charges                                                       | — |  |   | — |  |   | 24,198 |  |
| Impairment of other assets                                                        | — |  |   | — |  |   | 15,168 |  |
| Adjusted operating loss                                                           | (5,186 | ) |   | (2,452 | ) |   | (13,661 | ) |
| International                                                                     |   |   |   |   |   |
| Segment operating loss                                                            | (1,804 | ) |   | (294,043 | ) |   | (5,193 | ) |
| Impairment of investments                                                         | — |  |   | 280,066 |  |   | — |  |
| Gain on APAC JV ownership changes                                                 | — |  |   | — |  |   | (6,273 | ) |
| Adjusted operating loss                                                           | (1,804 | ) |   | (13,977 | ) |   | (11,466 | ) |
| Adjusted Other - Ancillary services and strategic initiatives operating loss | (6,990 | ) |   | (16,428 | ) |   | (25,127 | ) |
| Corporate administrative support:                                                 |   |   |   |   |   |
| Segment operating loss                                                            | (15,704 | ) |   | (12,378 | ) |   | (10,592 | ) |
| Adjusted Kidney Care operating income                                             | $ | 410,686 |  |   | $ | 430,403 |  |   | $ | 379,517 |  |

----

|                                                       |
|-------------------------------------------------------|
|                                                       |  |  |  |  |  |  |  |  |  |  |  |
|                                                  | Three months ended |
|                                                  | March 31,2018 |   | December 31,2017 |   | March 31,2017 |
| Income from continuing operations before income taxes | $ | 301,752 |  |   | $ | 46,825 |  |   | $ | 775,517 |  |
| Income tax expense (benefit)                          | $ | 70,737 |  |   | $ | (150,267 | ) |   | $ | 281,665 |  |
| Effective income tax rate                             | 23.4 | % |   | (320.9 | )% |   | 36.3 | % |

|                                                                                             |
|---------------------------------------------------------------------------------------------|
|                                                                                             |  |  |  |  |  |  |  |  |  |  |  |
|                                                                                        | Three months ended |
|                                                                                        | March 31,2018 |   | December 31,2017 |   | March 31,2017 |
| Income from continuing operations before income taxes                                       | $ | 301,752 |  |   | $ | 46,825 |  |   | $ | 775,517 |  |
| Less: Noncontrolling owners’ income primarily attributable to non-tax paying entities | (40,088 | ) |   | (41,019 | ) |   | (53,012 | ) |
| Income before income taxes attributable to DaVita Inc.                                      | $ | 261,664 |  |   | $ | 5,806 |  |   | $ | 722,505 |  |
|                                                                                        |   |   |   |   |   |
| Income tax expense (benefit)                                                                | $ | 70,737 |  |   | $ | (150,267 | ) |   | $ | 281,665 |  |
| Less: Income tax attributable to noncontrolling interests                                   | (88 | ) |   | (137 | ) |   | (65 | ) |
| Income tax expense (benefit) attributable to DaVita Inc.                                    | $ | 70,649 |  |   | $ | (150,404 | ) |   | $ | 281,600 |  |
|                                                                                        |   |   |   |   |   |
| Effective income tax rate attributable to DaVita Inc.                                       | 27.0 | % |   | (2,590.5 | )% |   | 39.0 | % |

----

|                                                                                            |
|--------------------------------------------------------------------------------------------|
|                                                                                            |  |  |  |  |  |  |  |  |  |  |  |
|                                                                                       | Three months ended |
| March 31,2018                                                                              |   | December 31,2017 |   | March 31,2017 |
| Income from continuing operations before income taxes                                      | $ | 301,752 |  |   | $ | 46,825 |  |   | $ | 775,517 |  |
| Goodwill impairment charges                                                                | — |  |   | — |  |   | 24,198 |  |
| Impairment of investments                                                                  | — |  |   | 280,066 |  |   | — |  |
| Impairment of other assets                                                                 | — |  |   | — |  |   | 15,168 |  |
| Gain on settlement, net                                                                    | — |  |   | — |  |   | (526,827 | ) |
| Equity investment income related to gain on settlement                                     | — |  |   | — |  |   | (2,677 | ) |
| Gain on APAC JV ownership changes                                                          | — |  |   | — |  |   | (6,273 | ) |
| Noncontrolling owners’ income primarily attributable to non-tax paying entities      | (40,088 | ) |   | (41,019 | ) |   | (53,012 | ) |
| Noncontrolling interests associated with adjustments                                       |   |   |   |   |   |
| Goodwill impairment charges                                                                | — |  |   | — |  |   | (6,880 | ) |
| Gain on settlement, net                                                                    | — |  |   | — |  |   | 24,029 |  |
| Adjusted income from continuing operations before income taxes attributable to DaVita Inc. | $ | 261,664 |  |   | $ | 285,872 |  |   | $ | 243,243 |  |
| Income tax expense (benefit)                                                               | $ | 70,737 |  |   | $ | (150,267 | ) |   | $ | 281,665 |  |
| Add income tax related to:                                                                 |   |   |   |   |   |
| Tax reform                                                                                 | — |  |   | 251,510 |  |   | — |  |
| Goodwill impairment charges                                                                | — |  |   | — |  |   | 6,568 |  |
| Impairment of investments                                                                  | — |  |   | 14,418 |  |   | — |  |
| Impairment of other assets                                                                 | — |  |   | — |  |   | 5,752 |  |
| Less income tax related to:                                                                |   |   |   |   |   |
| Gain on settlement, net                                                                    | — |  |   | — |  |   | (197,482 | ) |
| Noncontrolling interests                                                                   | (88 | ) |   | (137 | ) |   | (65 | ) |
| Adjusted income tax attributable to DaVita Inc.                                            | $ | 70,649 |  |   | $ | 115,524 |  |   | $ | 96,438 |  |
| Adjusted effective income tax rate attributable to DaVita Inc.                             | 27.0 | % |   | 40.4 | % |   | 39.6 | % |

----

|                                                                              |
|------------------------------------------------------------------------------|
|                                                                              |  |  |  |  |  |  |  |  |  |  |  |
|                                                                         | Three months ended |
|                                                                         | March 31,2018 |   | December 31,2017 |   | March 31,2017 |
| Cash provided by continuing operating activities                             | $ | 206,291 |  |   | $ | 286,716 |  |   | $ | 769,586 |  |
| Less: Distributions to noncontrolling interests                              | (45,467 | ) |   | (45,429 | ) |   | (43,316 | ) |
| Cash provided by continuing operating activities attributable to DaVita Inc. | 160,824 |  |   | 241,287 |  |   | 726,270 |  |
| Less: Expenditures for routine maintenance and information technology        | (99,268 | ) |   | (91,355 | ) |   | (69,302 | ) |
| Free cash flow from continuing operations                                    | $ | 61,556 |  |   | $ | 149,932 |  |   | $ | 656,968 |  |

|                                                                              |
|------------------------------------------------------------------------------|
|                                                                              |  |  |  |  |  |  |  |  |  |  |  |
|                                                                         | Rolling 12-Month Period |
|                                                                         | March 31,2018 |   | December 31,2017 |   | March 31,2017 |
| Cash provided by continuing operating activities                             | $ | 992,597 |  |   | $ | 1,555,892 |  |   | $ | 2,105,259 |  |
| Less: Distributions to noncontrolling interests                              | (213,043 | ) |   | (210,892 | ) |   | (185,089 | ) |
| Cash provided by continuing operating activities attributable to DaVita Inc. | 779,554 |  |   | 1,345,000 |  |   | 1,920,170 |  |
| Less: Expenditures for routine maintenance and information technology        | (332,663 | ) |   | (302,697 | ) |   | (309,311 | ) |
| Free cash flow from continuing operations                                    | $ | 446,891 |  |   | $ | 1,042,303 |  |   | $ | 1,610,859 |  |